Scaled Biolabs

About:

Scaled Biolabs accelerates discovery and development of cell therapies, leveraging microfluidics, automation and machine learning.

Website: http://www.scaledbiolabs.com/

Twitter/X: scaledbiolabs

Top Investors: IndieBio, SOSV, California Institute for Regenerative Medicine

Description:

Scaled Biolabs is pioneering a Cell Therapy Discovery Engine, working at the frontier of microfluidics, automation, and machine learning to develop best-in-class cell-based medicines. This engine enables leading biotech and pharma companies to survey hundreds of parameters across tens of thousands of experimental processes, providing an unprecedented window into cell-driven biology. This enables the development of novel and optimal cell-based products and processes, simplifying manufacturing, reducing time to market, and improving clinical outcomes. Scaled Biolabs also develops cell therapy assets internally, including a CIRM-funded program focusing on iPSC-derived dopaminergic neurons as a curative cell therapy for Parkinson’s disease.

Total Funding Amount:

$908000

Estimated Revenue Range:

Less than $1M

Headquarters Location:

San Francisco, California, United States

Founded Date:

2016-01-01

Contact Email:

mail(AT)scaledbiolabs.com

Founders:

Brendan Griffen, Drew Titmarsh, Justin Cooper-White

Number of Employees:

1-10

Last Funding Date:

2017-10-11

IPO Status:

Private

Industries:

© 2025 bioDAO.ai